Outlook Therapeutics (OTLK) Gains from Investment Securities (2015 - 2026)
Outlook Therapeutics (OTLK) reported Gains from Investment Securities of $480720.0 for Q1 2026, down 59.83% year-over-year from $1.2 million in Q1 2025, and down 82.78% quarter-over-quarter from $2.8 million in Q4 2025.
Outlook Therapeutics (OTLK) Gains from Investment Securities (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Gains from Investment Securities data on file, last reported at $480720.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $480720.0, down 59.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $480720.0 (down 59.83% YoY), and the FY2025 annual result was $125500.0, down 81.17% from the prior year.
- Gains from Investment Securities fell to $480720.0 in Q1 2026 per OTLK's latest filing, from $2.8 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $22.1 million in Q1 2023 and troughed at -$40.3 million in Q4 2024.
- A 5-year average of -$446727.8 and a median of $480720.0 in 2026 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities slumped 7651.24% in 2024, then soared 101454.6% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at -$30260.0 in 2022, then surged by 1862.49% to $533328.0 in 2023, then tumbled by 7651.24% to -$40.3 million in 2024, then jumped by 106.93% to $2.8 million in 2025, then sank by 82.78% to $480720.0 in 2026.
- Business Quant data shows OTLK's Gains from Investment Securities at $480720.0 in Q1 2026, $2.8 million in Q4 2025, and $64812.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Outlook Therapeutics | 63.14 Mn | 55.40 Mn | -21,888.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 480,720.00 |
| Mar 31, 2026 | 480,720.00 |
| Dec 31, 2025 | 2.79 Mn |
| Dec 31, 2025 | 2.79 Mn |
| Sep 30, 2025 | 64,812.00 |
| Sep 30, 2025 | 64,812.00 |
| Jun 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | -40.27 Mn |
| Dec 31, 2024 | -40.27 Mn |
| Sep 30, 2024 | 1,633.00 |
| Sep 30, 2024 | 1,633.00 |
| Jun 30, 2024 | 1,969.00 |
| Jun 30, 2024 | 1,969.00 |
| Mar 31, 2024 | 669,000.00 |
| Mar 31, 2024 | 669,000.00 |
| Dec 31, 2023 | 533,328.00 |
| Dec 31, 2023 | 533,328.00 |